Axplora

What Axplora does

Axplora Group GmbH is a privately held pharmaceutical CDMO (Contract Development and Manufacturing Organization) headquartered in Raubling, Germany, formed in 2023 from the merger of Farmabios (steroids/HPAPIs, Italy), Novasep CDMO (small molecules, ADCs, hazardous chemistry), and PharmaZell (specialty/generic APIs, Germany). The group operates nine API manufacturing sites across Germany, France, and India, plus a US R&D center in Wilmington, Delaware, and employs over 2,000 staff supporting more than 900 pharmaceutical and biotech customers.

The company specializes in complex small-molecule APIs, antibody-drug conjugates (ADCs), highly potent APIs (HPAPIs), and large-scale purification. Core proprietary technologies include Varicol continuous chromatography, Cyclojet single-column chromatography, and a patented solvent recycling process achieving >99.97% recovery, alongside differentiated capabilities in hazardous chemistry (azide, hydrazine, carbon disulfide), multi-ton-scale electrochemistry, flow chemistry, and solid-state chemistry. Axplora supplies payloads for 40% of the world's marketed ADCs and 50% of FDA-approved ADCs, with over 250 cGMP ADC batches produced and 1,000+ tons of commercial APIs manufactured, including ultra-purified omega-3 APIs.

Revenue is generated through B2B contract manufacturing services (process development, scale-up, clinical and commercial manufacturing) and API product sales to pharmaceutical innovators, biotechs, and generic drug manufacturers. Pricing is not publicly disclosed; contracts are negotiated directly with customers based on project scope, volume, and complexity. Distribution is exclusively direct enterprise sales supported by dedicated commercial teams and industry event presence. The company is led by CEO Martin Meeson (appointed April 2024, former CEO of Fujifilm Diosynth Biotechnologies).

Name

Axplora

Legal name

Axplora Group GmbH

Website

https://axplora.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Axplora is a Germany-based pharmaceutical CDMO formed in 2023 that specializes in complex small-molecule APIs, antibody-drug conjugates, HPAPIs, and large-scale purification across nine manufacturing sites in Europe, India, and the US, serving over 900 pharmaceutical and biotech customers with proprietary chromatography and hazardous chemistry capabilities.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• API contract manufacturing
• Pharmaceutical CDMO services
• ADC manufacturing solutions
• HPAPI production services
• Small molecule synthesis

Headquarters

HQ city

Raubling

HQ country

Germany

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Infrastructure, Supply Chain, Technology or R&D

Revenue model

1. CDMO Contract Manufacturing Services: Contract development and manufacturing services for pharmaceutical companies requiring complex APIs, ADCs, HPAPIs, and small molecule manufacturing. Services include process development, scale-up, clinical and commercial manufacturing.
2. API Product Sales: Sale of active pharmaceutical ingredients including steroids, omega-3, generic APIs, and specialty products to pharmaceutical companies worldwide.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Axplora is a Contract Development and Manufacturing Organization (CDMO) specializing in the development, process upscaling, and commercial manufacturing of complex active pharmaceutical ingredients (APIs) for pharmaceutical and biotech customers. Its offering covers antibody-drug conjugates (ADCs), highly potent APIs (HPAPIs), steroids, small molecules, omega-3 APIs, GLP-1 peptides, and specialty APIs through services spanning process development, scale-up, clinical and commercial manufacturing, and large-scale purification using proprietary chromatography technologies across 9 manufacturing sites in Europe, India, and the US.

Product overview

Axplora is a global CDMO (Contract Development and Manufacturing Organization) formed in 2023 through the merger of Farmabios, Novasep CDMO, and PharmaZell. The company operates as a unified group offering API products and CDMO solutions across 10 manufacturing sites on 3 continents (Europe, India, US) with over 2,000 employees serving 900+ customers. The portfolio consists of three main sub-brands: Farmabios (specializing in steroids and HPAPIs at its Italian site), Novasep CDMO (providing full-service contract manufacturing including ADC manufacturing, industrial chromatography, hazardous chemistry, flow chemistry, and electrochemistry), and PharmaZell (focused on specialty/generic APIs from its German headquarters). Core manufacturing capabilities include small molecule API synthesis, ADC manufacturing (payloads, conjugation, drug product), HPAPI manufacturing, GLP-1 peptide manufacturing, and large-scale purification services for omega-3 APIs and other complex molecules. The company leverages over 15 core technologies including chromatography, hazardous chemistry, flow chemistry, electrochemistry, and solid-state chemistry to serve pharmaceutical and biotech customers.

Differentiator

Problem solved

Functional benefit

Brands

• Dare to Imagine: Axplora's brand campaign aimed at positioning the company as bolder and more distinctive in the pharma CDMO space.

Products and services

• ADC Manufacturing Services End-to-end antibody-drug conjugate contract manufacturing for pharmaceutical and biotech customers, including payload synthesis, payload-linker production, bioconjugation, and drug product release testing. Axplora's Le Mans site supplies 40% of the world's marketed ADCs and 50% of FDA-approved ADCs.
• HPAPI Manufacturing Contract manufacturing of highly potent active pharmaceutical ingredients, including cytotoxic compounds, for pharmaceutical customers. Specialized facilities at Gropello Cairoli (Farmabios) support steroid and HPAPI synthesis with solid state expertise.
• Industrial Chromatography / Small Molecule Purification Large-scale purification services for APIs, intermediates, omega-3 fatty acids, natural extracts, peptides, oligonucleotides, and biologics. Uses proprietary Varicol and Cyclojet chromatography, SMB, HPLC, and low-pressure chromatography, with patented solvent recycling achieving 99.97% recovery.
• GLP-1 Peptide Manufacturing Large-scale contract manufacturing of GLP-1 receptor agonist peptide APIs targeting diabetes and obesity therapies. Includes peptide purification in biologics environment for next-generation GLP-1 therapies.
• Omega-3 API Purification Large-scale cGMP purification of ultra-purified omega-3 APIs (EPA, DHA) and poly-unsaturated fatty acids at Mourenx, using proprietary continuous chromatography with 99.97% solvent recycling.
• Hazardous Chemistry CDMO Services Contract manufacturing using energetic and hazardous reactions including azide, carbon disulfide, hydrazine chemistries, carbonylation, O2 oxidation, and reactions involving sodium cyanide. Leverkusen is the center of excellence and a major producer of nitroglycerin-based APIs.
• Flow Chemistry Continuous flow chemistry processing capabilities enabling safer, more efficient, and more sustainable chemical manufacturing processes for pharmaceutical customers.
• Electrochemistry CDMO Services Contract manufacturing using electrochemical reactions at multi-ton scale for API production, offering a distinctive alternative to traditional chemical synthesis routes. Raubling is the center of excellence.
• Solid State Chemistry Services Solid state chemistry expertise including polymorphism studies and particle size engineering to support API development and manufacturing, primarily for steroid and HPAPI programs at Farmabios.
• Lipid Production Contract manufacturing of lipids for pharmaceutical applications including lipid-based drug formulations and lipid nanoparticle excipients used in modern therapeutics.
• ADC Payloads Manufacturing Contract manufacturing of cytotoxic payload compounds for antibody-drug conjugates including Auristatins and Tecans, with dedicated Hastelloy reactor capacity at the Le Mans GMP workshop.
• Natural Extracts and Biomolecules Purification Purification services for natural (animal or plant) extracts and biomolecules, including peptides, oligonucleotides, and biologics, supporting customers from early-phase studies through commercial supply.
• Farmabios APIs (Steroids & HPAPI Products) Product offering of steroid APIs, HPAPIs, and specialty APIs produced by the Farmabios subsidiary at Gropello Cairoli, Italy, with comprehensive regulatory documentation.
• PharmaZell Specialty Products (Generic APIs) Product offering of generic APIs and specialty pharmaceutical ingredients including anti-inflammatory, gastrointestinal, and other established APIs, supplied to pharmaceutical customers worldwide.

Quantifiable outcome

• 40% of world's marketed ADCs manufactured by Axplora
• +5 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

One partnership is on record.

• France 2030 ProgramcoreStrategic or Co-development Partner · 1 March 2025Government investment program supporting Axplora's expansion of commercial payload production capabilities at Le Mans site. The France 2030 program recognizes biopharmaceutical manufacturing as a national priority and supports Axplora's position in ADC development and manufacturing in France.

Scale indicators15 records

Recent moves11 records

Expansion highlights6 records

Broad incumbents

• Lonza Group: The largest global CDMO offering small-molecule APIs, biologics, cell and gene therapy, and increasingly ADCs and peptide manufacturing. Directly comparable end-market and customer overlap with Axplora, but at much greater scale and broader modality coverage.
• Fareva: Privately held French-headquartered CDMO with strong API and finished-dose capabilities across Europe. Overlaps with Axplora's French manufacturing footprint and competes for European pharma outsourcing contracts.
• Catalent (Novo Holdings): Major global CDMO with extensive oral solid, biologics, and ADC drug-product capabilities acquired by Novo Holdings in 2024. Competes with Axplora for complex-API, drug-product, and fill-finish outsourcing from large pharma innovators.

Direct peers

• Hovione: Privately held CDMO specializing in complex small-molecule APIs, HPAPIs, and particle-engineering/continuous-manufacturing technologies. Closely comparable on the proprietary-technology axis (e.g., continuous processing) to Axplora's Pompey and Mourenx chromatography platform.
• EUROAPI: Spin-out of Sanofi's API business, focused on small-molecule and peptide APIs including steroids and complex chemistry. Direct competitor to Axplora/Farmabios in steroid APIs and generic APIs across European customers.
• Carbogen Amcis: Swiss-based CDMO (part of Dishman Carbogen Amcis) specializing in highly potent APIs, ADC payloads, and complex small-molecule chemistry. Direct competitor to Axplora's HPAPI, ADC payload, and hazardous chemistry offerings.
• Siegfried Holding: Swiss-listed CDMO focused on small-molecule API and drug-product manufacturing with sites in Switzerland, Germany, France, Spain, Malta, and the US. Highly comparable in customer mix, technology stack, and European footprint to Axplora's Novasep/PharmaZell operations.
• CordenPharma: Full-service CDMO covering APIs, drug products, peptides (including GLP-1s), lipids, HPAPIs, and ADCs across European sites. Closest direct peer to Axplora on modality breadth, especially the new GLP-1 and ADC franchises.
• Recipharm: European CDMO focused on small-molecule APIs and finished dosage forms, owned by EQT. Directly overlaps with Axplora's generic-API and small-molecule CDMO offerings, especially through the PharmaZell and Chasse-sur-Rhône operations.

Emerging players

• PolyPeptide Group: Peptide-focused CDMO serving GLP-1 and other therapeutic peptides, listed in Switzerland. Comparable to Axplora's newly announced Mourenx GLP-1 investment and a relevant competitor for peptide API outsourcing demand.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/axplora

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Axplora